.png){kind=logo}
Go beyond Fibrosis Staging
Currently used liver tests estimate the extent of fibrosis, missing the compensatory effects of liver regeneration and increased blood flow to extant functioning tissue.
HEPATIQ quantifies remaining liver function thus improving prediction of disease outcomes. To use a car analogy, other tests estimate the air in the gas tank. HEPATIQ measures the gas in the gas tank. HEPATIQ is FDA cleared and the only quantitative liver function product commercially available for routine use. The scan is covered by the patient's insurance.
HEPATIQ® -The Ultimate Liver Test®
The fed patient is injected with a low dose standard radioisotope - Tc99m sulfur colloid. A quick 20 minute SPECT scan of the liver is acquired. The HEPATIQ software analyzes these images to provide six indices of liver disease: quantitative liver function, steatosis/steatohepatitis, portal hypertension, alcoholic hepatitis, fibrosis stage and variceal size. It also provides a physiologic stage.
The HEPATIQ indices were proven to predict outcomes in the 8-year long multi-center HALT-C trial and outperformed all fibrosis tests. There are 28 publications on HEPATIQ and its clinical benefits. When fibrosis tests reach the “what now?” point, turn to HEPATIQ for more insight into the health of the liver.
TESTIMONIAL
Dr. Kip Lyche, Gastroenterologist.
Community Memorial Health System
"I have been using HEPATIQ in my gastroenterology practice and published a poster titled “Revolutionizing Care in Cirrhotic Patients Using HEPATIQ in a Community Setting” at the AASLD Liver Meeting in November 2022. Unlike the Child-Pugh class and the MELD score which indicate damage to the liver, the HEPATIQ indices provide true quantification of remaining liver function. Serial HEPATIQ testing has improved care for patients in my practice by providing accurate prognostic assessments based on trends in the PHM index of liver function. I believe HEPATIQ can provide early detection of progressive liver disease prompting a vigilant evaluation for complications."
MEDICAL CONFERENCES
Please visit our booth at the following conferences to discover more about HEPATIQ and have your questions answered.
- Digestive Disease Week (DDW), May 4-6, San Diego, Booth 1511.
- Society for Nuclear Medicine and Molecular Imaging (SNMMI), Jun 21-24, New Orleans, Booth 1642.
- Health Connect Partners (HCP) Radiology & Imaging Online Reverse Expo, Jul 22-24.
- American Society for Radiation Oncology (ASTRO), Sep 28-30, San Francisco, Booth 208.
- American College of Gastroenterology (ACG) Oct 26-28, Phoenix, Booth 1055.
- American Association for the Study of Liver Disease (AASLD), Nov 8-10, Washington DC, Booth 312.
- Radiological Society of North America (RSNA), Nov 30-Dec 3, Chicago, Booth 6804.
- Society of Interventional Oncology (SIO), Feb 4-8, 2026, Savannah, Georgia.
- Society of Interventional Radiology (SIR), Apr 11-15, 2026, Toronto.